glp 1 agonist osteoporosis GLP-1s and Bone Health: What the Evidence Says About Semaglutide, Bone Density, and Muscle Loss Treatment of Diabetes and Osteoporosis—A

Propensity score fine stratification weighted Cox proportional hazards models were fitted to estimate hazard ratios and 95% confidence intervals (CIs) to estimate the average treatment effect among the treated patients

CivicScience offers insights into the impact of cost, side effects & trends in GLP-1 usage.

Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases

Despite their exploding popularity, the current GLP-1 injections (semaglutide though is also orally available) face accessibility issues due to cost and adverse effects and thus the next big move for the space, an easy to - pop pill could be lucrative, for which clinical trials are already well underway

A dual GIP/GLP-1 agonist studied in metabolic research

Preclinical studies have confirmed that GIPRGLP1R coagonists improve several hallmarks of metabolic syndrome, such as obesity, hyperglycemia, and dyslipidemia